Your browser doesn't support javascript.
Comparison of mRNA Vaccinations with BNT162b2 or mRNA-1273 in Anti-CD20-Treated Multiple Sclerosis Patients.
Hammer, Helly; Hoepner, Robert; Friedli, Christoph; Leib, Stephen L; Suter-Riniker, Franziska; Diem, Lara; Kamber, Nicole; Chan, Andrew; Salmen, Anke; Kamm, Christian P.
  • Hammer H; Department of Neurology, Inselspital, Bern University Hospital and University of Bern, 3010 Bern, Switzerland.
  • Hoepner R; Department of Neurology, Inselspital, Bern University Hospital and University of Bern, 3010 Bern, Switzerland.
  • Friedli C; Department of Neurology, Inselspital, Bern University Hospital and University of Bern, 3010 Bern, Switzerland.
  • Leib SL; Institute for Infectious Diseases, University of Bern, 3010 Bern, Switzerland.
  • Suter-Riniker F; Institute for Infectious Diseases, University of Bern, 3010 Bern, Switzerland.
  • Diem L; Department of Neurology, Inselspital, Bern University Hospital and University of Bern, 3010 Bern, Switzerland.
  • Kamber N; Department of Neurology, Inselspital, Bern University Hospital and University of Bern, 3010 Bern, Switzerland.
  • Chan A; Department of Neurology, Inselspital, Bern University Hospital and University of Bern, 3010 Bern, Switzerland.
  • Salmen A; Department of Neurology, Inselspital, Bern University Hospital and University of Bern, 3010 Bern, Switzerland.
  • Kamm CP; Department of Neurology, Inselspital, Bern University Hospital and University of Bern, 3010 Bern, Switzerland.
Vaccines (Basel) ; 10(6)2022 Jun 09.
Article in English | MEDLINE | ID: covidwho-1884446
ABSTRACT

Objective:

Anti-CD20-treated patients are at risk of a reduced humoral immune response during the SARS-CoV-2 pandemic. Our aim was to compare the antibody response after two vaccinations with the mRNA vaccines BNT162b2 or mRNA-1273 in patients with multiple sclerosis.

Methods:

Data from the University Hospital of Bern and Cantonal Hospital of Lucerne were retrospectively collected from medical records and then analyzed. Anti-spike IgG serum titers were collected from both centers and were considered to be protective from a value of ≥100 AU/mL. Continuous variables were given as the mean and 95% confidence interval (95% CI); categorical variables were given as frequencies. A Mann-Whitney test and Fisher's exact test as well as a multivariable linear regression analysis with anti-spike IgG (AU/mL) as the dependent variable were run using SPSS Statistic 25 (IBM Corp., Amonk, NY, USA).

Results:

A total of 74 patients were included; 41/74 (63.51%) were female patients and the mean age was 46.6 years (95% CI 43.4-49.9). Of these patients, 36/74 were vaccinated with BNT162b2 and 38/74 with mRNA-1273, following the national vaccination recommendation. In both vaccine groups, protective anti-spike IgG titers (≥100 AU/mL) were infrequently achieved (5/74 mRNA-1273 3/38; BNT162b2 2/36).

Conclusions:

In addition to a low rate of protective anti-spike IgG titers in both vaccine groups, we identified a drop in anti-spike IgG serum titers over time. This observation bears therapeutic consequences, as initial positive titers should be checked in case of an infection with the SARS-CoV-2 virus to identify patients who would benefit from an intravenous anti-spike IgG treatment against acute COVID-19.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10060922

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10060922